Gibbs JB, Oliff A. Pharmaceutical research in molecular oncology. Cell. 1994;79:193–8.

Article  CAS  PubMed  Google Scholar 

Wang JJ, Lei KF, Han F. Tumor microenvironment: recent advances in various cancer treatments. Eur Rev Med Pharm Sci. 2018;22:3855–64.

Google Scholar 

Moodie SA, Wolfman A. The 3Rs of life: Ras, Raf and growth regulation. Trends Genet. 1994;10:44–48.

Article  CAS  PubMed  Google Scholar 

Chen S, Li F, Xu D, et al. The Function of RAS Mutation in Cancer and Advances in its Drug Research. Curr Pharm Des. 2019;25:1105–14.

Article  CAS  PubMed  Google Scholar 

Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22.

Article  CAS  PubMed  Google Scholar 

Dai W, Xie S, Chen C, et al. Ras sumoylation in cell signaling and transformation. Semin Cancer Biol. 2021;76:301–9.

Article  CAS  PubMed  Google Scholar 

Dunnett-Kane V, Nicola P, Blackhall F, et al. Mechanisms of Resistance to KRASG12C Inhibitors. Cancers. 2021;13:151.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129:1287–92.

CAS  PubMed  PubMed Central  Google Scholar 

Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631–52.

Article  CAS  PubMed  Google Scholar 

Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell. 2005;7:297–300.

Article  CAS  PubMed  Google Scholar 

Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res. 2006;47:15–31.

Article  CAS  PubMed  Google Scholar 

Lobell RB. Prenylation of Ras GTPase superfamily proteins and their function in immunobiology. Adv Immunol. 1998;68:145–89.

Article  CAS  PubMed  Google Scholar 

Silva LR, da Silva-Júnior EF. Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products. Curr Med Chem. 2022;29:189–11.

Article  CAS  PubMed  Google Scholar 

Wang Q, Chen F, Liu P, et al. Scaffold-based analysis of nonpeptide oncogenic FTase inhibitors using multiple similarity matching, binding affinity scoring and enzyme inhibition assay. J Mol Graph Model. 2021;105:107898.

Article  CAS  PubMed  Google Scholar 

Jones HA, Hahn SM, Bernhard E, et al. Ras inhibitors and radiation therapy. Semin Radiat Oncol. 2001;11:328–37.

Article  CAS  PubMed  Google Scholar 

Nam NH, Parang K. Current targets for anticancer drug discovery. Curr Drug Targets. 2003;4:159–79.

Article  CAS  PubMed  Google Scholar 

Dhillon S. Lonafarnib: First Approval [published correction appears in Drugs. 2021 Apr;81(5):619]. Drugs. 2021;81:283–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kohl NE. Farnesyltransferase inhibitors. Preclinical development. Ann NY Acad Sci. 1999;886:91–102.

Article  CAS  PubMed  Google Scholar 

Wang J, Yao X, Huang J. New tricks for human farnesyltransferase inhibitor: cancer and beyond. Medchemcomm. 2017;8:841–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cho KN, Lee KI. Chemistry and biology of Ras farnesyltransferase. Arch Pharm Res. 2002;25:759–69.

Article  CAS  PubMed  Google Scholar 

Morgillo F, Lee HY. Lonafarnib in cancer therapy. Expert Opin Investig Drugs. 2006;15:709–19.

Article  CAS  PubMed  Google Scholar 

Mullard A. The FDA approves a first farnesyltransferase inhibitor. Nat Rev Drug Discov. 2021;20:8.

Article  PubMed  Google Scholar 

George Njoroge F, Taveras AG, Kelly J, et al. -4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): A Very Potent Farnesyl Protein Transferase Inhibitor as a Novel Antitumor Agent. J Med Chem. 1998;41:4890–4902.

Article  Google Scholar 

Suzuki M, Jeng LJB, Chefo S, et al. FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. Genet Med. 2023;25:100335.

Article  CAS  PubMed  Google Scholar 

Arnold R, Vehns E, Randl H, et al. Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells. Int J Mol Sci. 2021;22:7474.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abuhaie CM, Ghinet A, Farce A, et al. Synthesis and biological evaluation of a new series of phenothiazine-containing protein farnesyltransferase inhibitors. Eur J Med Chem. 2013;59:101–10.

Article  CAS  PubMed  Google Scholar 

Dumitriu GM, Ghinet A, Bîcu E, et al. Peptide chemistry applied to a new family of phenothiazine-containing inhibitors of human farnesyltransferase. Bioorg Med Chem Lett. 2014;24:3180–5.

Article  CAS  PubMed  Google Scholar 

Dumitriu GM, Bîcu E, Belei D, et al. Phenothiazine-based CaaX competitive inhibitors of human farnesyltransferase bearing a cysteine, methionine, serine or valine moiety as a new family of antitumoral compounds. Bioorg Med Chem Lett. 2015;25:4447–52.

Article  CAS  PubMed  Google Scholar 

Moise IM, Ghinet A, Belei D, et al. New indolizine-chalcones as potent inhibitors of human farnesyltransferase: Design, synthesis and biological evaluation. Bioorg Med Chem Lett. 2016;26:3730–4.

Article  CAS  PubMed  Google Scholar 

Moise IM, Bîcu E, Farce A, et al. Indolizine-phenothiazine hybrids as the first dual inhibitors of tubulin polymerization and farnesyltransferase with synergistic antitumor activity. Bioorg Chem. 2020;103:104184.

Article  CAS  PubMed  Google Scholar 

Dumitriu G-M, Ghinet A, Belei D, et al. Investigation of New Phenothiazine and Carbazole Derivatives as Potential Inhibitors of Human Farnesyltransferase. Lett Drug Des Discov. 2015;12:85–92.

Article  CAS  Google Scholar 

Ghasemi S, Sharifi S, Davaran S, et al. Synthesis and cytotoxicity evaluation of some novel 1-(3-Chlorophenyl) piperazin-2-one derivatives bearing imidazole bioisosteres. Aust J Chem. 2013;66:655–60.

Article  CAS  Google Scholar 

Ghasemi S, Sharifi S, Shahbazi Mojarrad J. Design, Synthesis and Biological Evaluation of Novel Piperazinone Derivatives as Cytotoxic Agents. Adv Pharm Bull. 2020;10:423–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abuhaie CM, Ghinet A, Farce A, et al. Synthesis and biological evaluation of a new series of N-ylides as protein farnesyltransferase inhibitors. Bioorg Med Chem Lett. 2013;23:5887–92.

Article  CAS  PubMed  Google Scholar 

Dumea C, Belei D, Ghinet A, et al. Novel indolizine derivatives with unprecedented inhibitory activity on human farnesyltransferase. Bioorg Med Chem Lett. 2014;24:5777–81.

Article  CAS  PubMed  Google Scholar 

Yang L, Liu W, Mei H, et al. Synthesis and biological evaluation of pentanedioic acid derivatives as farnesyltransferase inhibitors. Medchemcomm. 2015;6:671–6.

Article  CAS  Google Scholar 

Lucescu L, Bîcu E, Belei D, et al. Synthesis and biological evaluation of a new class of triazin-triazoles as potential inhibitors of human farnesyltransferase. Res Chem Intermed. 2016;42:1999–2021.

Article  CAS  Google Scholar 

Homerin G, Lipka E, Rigo B, et al. On the discovery of new potent human farnesyltransferase inhibitors: emerging pyroglutamic derivatives. Org Biomol Chem. 2017;15:8110–8.

Article  CAS  PubMed  Google Scholar 

Jin Y, Li L, Yang Z, et al. The discovery of a novel compound with potent antitumor activity: virtual screening, synthesis, biological evaluation and preliminary mechanism study. Oncotarget. 2017;8:24635–43.

Article